Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Paliperidone Palmitate · 1 trial · 1 indication
Change within treatment groups of Positive and Negative Syndrome Scale (PANSS) total score between baseline and week 4 based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.
| Arm | Type | Description |
|---|---|---|
| Treatment Group 1 | EXPERIMENTAL | Regular injections |
| Treatment Group 2 | ACTIVE_COMPARATOR | Regular injections |
| Name | Type | Description |
|---|---|---|
| Aripiprazole Lauroxil | COMBINATION_PRODUCT | Intramuscular injection; study drug provided using a pre-filled syringe |
| Paliperidone Palmitate | DRUG | Intramuscular injection |
Inclusion Criteria: * Has a diagnosis of schizophrenia * Requires acute treatment for symptoms of schizophrenia * Willing and able to be confined to an inpatient study unit for up to 3-4 weeks * Has experienced at least one previous hospitalization for schizophrenia * Has been able to achieve outpa...
Paliperidone Palmitate is used for the treatment of schizophrenia. It is a small molecule being developed by Alkermes plc for this psychiatric condition. The drug is currently in Phase 3 clinical development, meaning it is investigational and has not yet been approved for use.
Paliperidone Palmitate is being developed by Alkermes plc, a biopharmaceutical company traded on the stock exchange under the ticker ALKS. The company is conducting clinical trials to evaluate the drug's safety and efficacy for the treatment of schizophrenia.
Paliperidone Palmitate is in Phase 3 clinical development for schizophrenia. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 3 trial has been completed, but the drug remains under clinical investigation.
Paliperidone Palmitate was studied in a Phase 3 clinical trial with the identifier NCT03345979. This completed trial, titled 'A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia,' enrolled 200 participants in the United States. The study was randomized, double-blind, and active-controlled.
No, Paliperidone Palmitate is not the same as Aripiprazole Lauroxil. They are different drugs that were compared in a clinical trial for the treatment of schizophrenia. The trial NCT03345979 evaluated both medications to assess their effects in patients with this condition.